These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38266966)

  • 1. Effect of Mavacamten on Hypertrophic Cardiomyopathy Patients With Left Ventricular Outflow Tract Obstruction Provoked Only Postexercise or With Amyl Nitrite.
    Roehl K; Suppah M; Geske J; Newman D; Giudicessi J; Ackerman M; Ommen S; Alsidawi S
    J Am Soc Echocardiogr; 2024 May; 37(5):566-568. PubMed ID: 38266966
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of Valsalva Maneuver, Amyl Nitrite, and Exercise Echocardiography to Demonstrate Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy.
    Ayoub C; Geske JB; Larsen CM; Scott CG; Klarich KW; Pellikka PA
    Am J Cardiol; 2017 Dec; 120(12):2265-2271. PubMed ID: 29054275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy.
    Marwick TH; Nakatani S; Haluska B; Thomas JD; Lever HM
    Am J Cardiol; 1995 Apr; 75(12):805-9. PubMed ID: 7717284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
    Heitner SB; Jacoby D; Lester SJ; Owens A; Wang A; Zhang D; Lambing J; Lee J; Semigran M; Sehnert AJ
    Ann Intern Med; 2019 Jun; 170(11):741-748. PubMed ID: 31035291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Doppler echocardiography and amyl nitrite inhalation to characterize left ventricular outflow obstruction in hypertrophic cardiomyopathy.
    Sheikh KH; Pearce FB; Kisslo J
    Chest; 1990 Feb; 97(2):389-95. PubMed ID: 1967573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction.
    Schaff HV; Dearani JA; Ommen SR; Sorajja P; Nishimura RA
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):303-9. PubMed ID: 22154797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.
    Masri A; Lester SJ; Stendahl JC; Hegde SM; Sehnert AJ; Balaratnam G; Shah A; Fox S; Wang A
    J Am Heart Assoc; 2024 Apr; 13(8):e030607. PubMed ID: 38591260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of mavacamten in patients with hypertrophic cardiomyopathy.
    Liao HL; Liang Y; Liang B
    J Cardiovasc Med (Hagerstown); 2024 Jul; 25(7):491-498. PubMed ID: 38814051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM.
    Elliott PM
    Cardiovasc Res; 2020 Nov; 116(13):e175-e178. PubMed ID: 33096564
    [No Abstract]   [Full Text] [Related]  

  • 13. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
    Chase Cole J; Benvie SF; DeLosSantos M
    Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
    Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
    JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
    Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
    Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics.
    Lafitte S; Reant P; Touche C; Pillois X; Dijos M; Arsac F; Peyrou J; Montaudon M; Ritter P; Roudaut R; Demaria A
    J Am Coll Cardiol; 2013 Aug; 62(9):842-50. PubMed ID: 23810875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story.
    Maron BJ; Rowin EJ; Maron MS
    Am J Cardiol; 2021 May; 147():145-146. PubMed ID: 33549527
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
    Bertero E; Chiti C; Schiavo MA; Tini G; Costa P; Todiere G; Mabritto B; Dei LL; Giannattasio A; Mariani D; Lofiego C; Santolamazza C; Monda E; Quarta G; Barbisan D; Mandoli GE; Mapelli M; Sguazzotti M; Negri F; De Vecchi S; Ciabatti M; Tomasoni D; Mazzanti A; Marzo F; de Gregorio C; Raineri C; Vianello PF; Marchi A; Biagioni G; Insinna E; Parisi V; Ditaranto R; Barison A; Giammarresi A; De Ferrari GM; Priori S; Metra M; Pieroni M; Patti G; Imazio M; Perugini E; Agostoni P; Cameli M; Merlo M; Sinagra G; Senni M; Limongelli G; Ammirati E; Vagnarelli F; Crotti L; Badano L; Calore C; Gabrielli D; Re F; Musumeci G; Emdin M; Barbato E; Musumeci B; Autore C; Biagini E; Porto I; Olivotto I; Canepa M
    Eur J Heart Fail; 2024 Jan; 26(1):59-64. PubMed ID: 38131253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mavacamten - the first disease-specific pharmacological treatment of hypertrophic cardiomyopathy].
    Magnusson P; Karason K
    Lakartidningen; 2021 Aug; 118():. PubMed ID: 34498248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.